Last updated on March 2019

Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection


Brief description of study

This study will have 2 parts: Pharmacokinetics (PK) Lead-in Phase and the Treatment Phase.

The primary objective of the PK Lead-in Phase is to evaluate the steady state PK and confirm the dose of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in pediatric participants with chronic hepatitis C virus (HCV) infection.

The primary objective of the Treatment Phase is to evaluate the safety and tolerability of SOF/VEL for 12 weeks in pediatric participants with chronic HCV.

Clinical Study Identifier: NCT03022981

Contact Investigators or Research Sites near you

Start Over

Gilead Clinical Study Information Center

Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.